[1]
|
Title of Cancer Stat Facts: Ovarian Cancer. https://seer.cancer.gov/statfacts/html/ovary.html
|
[2]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Morta lity Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[3]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2019) Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 7-34. https://doi.org/10.3322/caac.21551
|
[4]
|
Bast Jr., R.C., Feeney, M., Lazarus, H., Nadler, L.M., Colvin, R.B. and Knapp, R.C. (1981) Reactivity of a Monoclonal Antibody with Human Ovarian Carcinoma. The Journal of Clinical Investigation, 68, 1331-1337. https://doi.org/10.1172/JCI110380
|
[5]
|
Bast Jr., R.C., Klug, T.L., St John, E., Jenison, E., Niloff, J.M., Lazarus, H., Berkowitz, R.S., Leavitt, T., Griffiths, C.T., Parker, L., Zurawski Jr., V.R., and Knapp, R.C. (1983) A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer. The New England Journal of Medicine, 309, 883-887. https://doi.org/10.1056/NEJM198310133091503
|
[6]
|
Van Haaften-Day, C., Shen, Y., Xu, F., Yu, Y., Berchuck, A., Havrilesky, L.J., Hacker, N.F., et al. (2001) OVX1, Macrophage-Colony Stimulating Factor, and CA-125-II as Tumor Markers for Epithelial Ovarian Carcinoma: A Critical Appraisal. Cancer, 92, 2837-2844. https://doi.org/10.1002/1097-0142(20011201)92:11<2837::AID-CNCR10093>3.0.CO;2-5
|
[7]
|
Jelovac, D. and Armstrong, D.K. (2011) Recent Progress in the Diagnosis and Treatment of Ovarian Cancer. CA: A Cancer Journal for Clinicians, 61, 183-203. https://doi.org/10.3322/caac.20113
|
[8]
|
Van Gorp, T., Cadron, I., Despierre, E., Daemen, A., Leunen, K., Amant, F., Timmerman, D., De Moor, B. and Vergote, I. (2011) HE4 and CA125 as a Diagnostic Test in Ovarian Cancer: Prospective Validation of the Risk of Ovarian Malignancy Algorithm. British Journal of Cancer, 104, 863-870. https://doi.org/10.1038/sj.bjc.6606092
|
[9]
|
Chan, K.K., Chen, C.A., Nam, J.H., Ochiai, K., Wilailak, S., Choon, A.T., et al. (2013) The Use of HE4 in the Prediction of Ovarian Cancer in Asian Women with a Pelvic Mass. Gynecologic Oncology, 128, 239-244. https://doi.org/10.1016/j.ygyno.2012.09.034
|
[10]
|
Pauler, D.K., Menon, U., McIntosh, M., Symecko, H.L., Skates, S.J. and Jacobs, I.J. (2001) Factors Influencing Serum CA125II Levels in Healthy Postmenopausal Women. Cancer Epidemiology, Biomarkers & Prevention, 10, 489-493.
|
[11]
|
Hirsch, M., Duffy, J., Davis, C.J., Nieves Plana, M., Khan, K.S. and International Collaboration to Harmonise Outcomes and Measures for Endometriosis (2016) Diagnostic Accuracy of Cancer Antigen 125 for Endometriosis: A Systematic Review and Meta-Analysis. BJOG: An International Journal of Obstetrics & Gynaecology, 123, 1761-1768. https://doi.org/10.1111/1471-0528.14055
|
[12]
|
Morshed, G. and Fathy, S.M. (2016) Impact of Post-Laparoscopic Sleeve Gastrectomy Weight Loss on C-Reactive Protein, Lipid Profile and CA-125 in Morbidly Obese Women. Videosurgery and Other Miniinvasive Techniques, 10, 521-526. https://doi.org/10.5114/wiitm.2015.56480
|
[13]
|
Monteiro, S., Franco, F., Costa, S., Monteiro, P., Vieira, H., Coelho, L., Oliveira, L. and Providência, L.A. (2010) Prognostic Value of CA125 in Advanced Heart Failure Patients. International Journal of Cardiology, 140, 115-118. https://doi.org/10.1016/j.ijcard.2008.11.023
|
[14]
|
Moss, E.L., Hollingworth, J. and Reynolds, T.M. (2005) The Role of CA125 in Clinical Practice. Journal of Clinical Pathology, 58, 308-312. https://doi.org/10.1136/jcp.2004.018077
|
[15]
|
Yu, S., Yang, H.J., Xie, S.Q. and Bao, Y.X. (2012) Diagnostic Value of HE4 for Ovarian Cancer: A Meta-Analysis. Clinical Chemistry and Laboratory Medicine, 50, 1439-1446. https://doi.org/10.1515/cclm-2011-0477
|
[16]
|
Ferraro, S., Braga, F., Lanzoni, M., Boracchi, P., Biganzoli, E.M. and Panteghini, M. (2013) Serum Human Epididymis Protein 4 vs Carbohydrate Antigen 125 for Ovarian Cancer Diagnosis: A Systematic Review. Journal of Clinical Pathology, 66, 273-281. https://doi.org/10.1136/jclinpath-2012-201031
|
[17]
|
Zhang, M., Cheng, S., Jin, Y., Zhao, Y. and Wang, Y. (2021) Roles of CA125 in Diagnosis, Prediction, and Oncogenesis of Ovarian Cancer. Biochimica et Biophysica Acta. Reviews on Cancer, 1875, Article 188503. https://doi.org/10.1016/j.bbcan.2021.188503
|
[18]
|
Dochez, V., Caillon, H., Vaucel, E., Dimet, J., Winer, N. and Ducarme, G. (2019) Biomarkers and Algorithms for Diagnosis of Ovarian Cancer: CA125, HE4, RMI and ROMA, a Review. Journal of Ovarian Research, 12, Article No. 28. https://doi.org/10.1186/s13048-019-0503-7
|
[19]
|
Ueland, F.R., Desimone, C.P., Seamon, L.G., Miller, R.A., Goodrich, S., Podzielinski, I., Sokoll, L., Smith, A., van Nagell Jr., J.R., and Zhang, Z. (2011) Effectiveness of a Multivariate Index Assay in the Preoperative Assessment of Ovarian Tumors. Obstetrics and Gynecology, 117, 1289-1297. https://doi.org/10.1097/AOG.0b013e31821b5118
|
[20]
|
Coleman, R.L., Herzog, T.J., Chan, D.W., Munroe, D.G., Pappas, T.C., Smith, A., Zhang, Z. and Wolf, J. (2016) Validation of a Second-Generation Multivariate Index Assay for Malignancy Risk of Adnexal Masses. American Journal of Obstetrics and Gynecology, 215, 82.e1-82. e11. https://doi.org/10.1016/j.ajog.2016.03.003
|
[21]
|
Andersen, M.R., Goff, B.A., Lowe, K.A., Scholler, N., Bergan, L., Drescher, C.W., Paley, P. and Urban, N. (2010) Use of a Symptom Index, CA125, and HE4 to Predict Ovarian Cancer. Gynecologic Oncology, 116, 378-383. https://doi.org/10.1016/j.ygyno.2009.10.087
|
[22]
|
Zhang, Z., Yu, Y., Xu, F., Berchuck, A., van Haaften-Day, C., Havrilesky, L.J., de Bruijn, H.W., van der Zee, A.G., Woolas, R.P., Jacobs, I.J., Skates, S., Chan, D.W. and Bast Jr., R.C. (2007) Combining Multiple Serum Tumor Markers Improves Detection of Stage I Epithelial Ovarian Cancer. Gynecologic Oncology, 107, 526-531. https://doi.org/10.1016/j.ygyno.2007.08.009
|
[23]
|
Cramer, D.W., Fichorova, R.N., Terry, K.L., Yamamoto, H., Vitonis, A.F., Ardanaz, E., Aune, D., Boeing, H., Brändstedt, J., Boutron-Ruault, M.C., Chirlaque, M.D., Dorronsoro, M., Dossus, L., Duell, E.J., Gram, I.T., Gunter, M., Hansen, L., Idahl, A., Johnson, T., Khaw, K.T., Kaaks, R., et al. (2018) Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort. Cancer Epidemiology, Biomarkers & Prevention, 27, 790-804. https://doi.org/10.1158/1055-9965.EPI-17-0744
|
[24]
|
Köbel, M., Kalloger, S.E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N.J., Ionescu, D.N., Rajput, A., Prentice, L.M., Miller, D., Santos, J., Swenerton, K., Gilks, C.B. and Huntsman, D. (2008) Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies. PLOS Medicine, 5, e232. https://doi.org/10.1371/journal.pmed.0050232
|
[25]
|
Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F.O., Narod, S.A. and Akbari, M.R. (2020) CA125 and Ovarian Cancer: A Comprehensive Review. Cancers, 12, Article 3730. https://doi.org/10.3390/cancers12123730
|
[26]
|
Nezhat, F.R., Apostol, R., Nezhat, C. and Pejovic, T. (2015) New Insights in the Pathophysiology of Ovarian Cancer and Implications for Screening and Prevention. American Journal of Obstetrics and Gynecology, 213, 262-267. https://doi.org/10.1016/j.ajog.2015.03.044
|
[27]
|
Lu, D., Kuhn, E., Bristow, R.E., Giuntoli 2nd., R.L., Kjær, S.K., Shih, I.M. and Roden, R.B. (2011) Comparison of Candidate Serologic Markers for Type I and Type II Ovarian Cancer. Gynecologic Oncology, 122, 560-566. https://doi.org/10.1016/j.ygyno.2011.05.039
|
[28]
|
Peng, X. and Liu, J. (2023) 791P Development and Validation of Nomograms to Predict Survival in Patients with High-Grade Serous Ovarian Cancer. Annals of Oncology, 34, S531. https://doi.org/10.1016/j.annonc.2023.09.1969
|
[29]
|
Colomban, O., Tod, M., Leary, A., Ray-Coquard, I., Lortholary, A., Hardy-Bessard, A.C., Pfisterer, J., Du Bois, A., Kurzeder, C., Burges, A., Péron, J., Freyer, G. and You, B. (2019) Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study. Clinical Cancer Research, 25, 5342-5350. https://doi.org/10.1158/1078-0432.CCR-18-3335
|
[30]
|
You, B., Robelin, P., Tod, M., Louvet, C., Lotz, J.-P., Abadie-Lacourtoisie, S., Colomban, O., et al. (2020) CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. Clinical Cancer Research, 26, 4625-4632. https://doi.org/10.1158/1078-0432.CCR-20-0054
|
[31]
|
Lauby, A., Colomban, O., Corbaux, P., Peron, J., Van Wagensveld, L., Gertych, W., Bakrin, N., Descargues, P., Lopez, J., Kepenekian, V., Glehen, O., Philip, C.A., Devouassoux-Shisheboran, M., Tod, M., Freyer, G. and You, B. (2021) The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review. Cancers, 14, Article 98. https://doi.org/10.3390/cancers14010098
|
[32]
|
Salani, R., Backes, F.J., Fung, M.F., Holschneider, C.H., Parker, L.P., Bristow, R.E. and Goff, B.A. (2011) Posttreatment Surveillance and Diagnosis of Recurrence in Women with Gynecologic Malignancies: Society of Gynecologic Oncologists Recommendations. American Journal of Obstetrics and Gynecology, 204, 466-478. https://doi.org/10.1016/j.ajog.2011.03.008
|
[33]
|
Colombo, N., Lorusso, D. and Scollo, P. (2017) Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future. International Journal of Gynecological Cancer, 27, 1134-1140. https://doi.org/10.1097/IGC.0000000000001023
|
[34]
|
Marcus, C.S., Maxwell, G.L., Darcy, K.M., Hamilton, C.A. and McGuire, W.P. (2014) Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer. Journal of Cancer, 5, 25-30. https://doi.org/10.7150/jca.7810
|
[35]
|
Rustin, G.J., van der Burg, M.E., Griffin, C.L., Guthrie, D., Lamont, A., Jayson, G.C., Kristensen, G., Mediola, C., Coens, C., Qian, W., Parmar, M.K., Swart, A.M. for the MRC OV05 and EORTC 55955 Investigators (2010) Early versus Delayed Treatment of Relapsed Ovarian Cancer (MRC OV05/EORTC 55955): A Randomised Trial. The Lancet, 376, 1155-1163. https://doi.org/10.1016/S0140-6736(10)61268-8
|
[36]
|
Rustin, G.J.S., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., et al. (2011) Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). International Journal of Gynecological Cancer, 21, 419-423. https://doi.org/10.1097/IGC.0b013e3182070f17
|
[37]
|
Lu, H.-W., Ye, D.-D., Wu, B., et al. (2023) Interpretation of NCCN Clinical Practice Guidelines for Ovary Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer in 2023 (1st Edition). Chinese Journal of Practical Gynecology and Obstetrics, 39, 58-67.
|
[38]
|
Gadducci, A., Fuso, L., Cosio, S., Landoni, F., Maggino, T., Perotto, S., Sartori, E., Testa, A., Galletto, L. and Zola, P. (2009) Are Surveillance Procedures of Clinical Benefit for Patients Treated for Ovarian Cancer? A Retrospective Italian Multicentric Study. International Journal of Gynecological Cancer, 19, 367-374. https://doi.org/10.1111/IGC.0b013e3181a1cc02
|
[39]
|
Wang, F., Ye, Y., Xu, X., Zhou, X., Wang, J. and Chen, X. (2013) CA-125-Indicated Asymptomatic Relapse Confers Survival Benefit to Ovarian Cancer Patients Who Underwent Secondary Cytoreduction Surgery. Journal of Ovarian Research, 6, Article No. 14. https://doi.org/10.1186/1757-2215-6-14
|
[40]
|
Levy, T., Weiser, R., Boaz, M., Shem, E.B., Golan, A. and Menczer, J. (2012) Prognostic Significance of Rising Serum CA-125 Levels within the Normal Range in Patients with Epithelial Ovarian, Primary Peritoneal, and Tubal Cancers, Who, after Initial Treatment, Had a Complete Clinical Response. International Journal of Gynecological Cancer, 22, 1344-1348. https://doi.org/10.1097/IGC.0b013e3182691254
|
[41]
|
Qin, X., Liu, X.-L., Wang, X.-Y., et al. (2016) Clinical Significance of Serum CA125 in Prognosis Evaluation and Recurrence Monitoring of Epithelial Ovarian Cancer. Chinese Journal of Practical Gynecology and Obstetrics, 32, 473-476.
|
[42]
|
Giuliani, M., Gui, B., Valentini, A.L., DI Giovanni, S.E., Miccò, M., Rodolfino, E., Falcione, M., de Waure, C., Palluzzi, E., Salutari, V., Scambia, G. and Manfredi, R. (2017) Early Detection of Recurrence or Progression Disease in Patients with Ovarian Cancer after Primary Debulking Surgery. Correlation between CT Findings and CA 125 Levels. Minerva Ginecologica, 69, 538-547. https://doi.org/10.23736/S0026-4784.17.04062-X
|
[43]
|
Riedinger, J.M., Wafflart, J., Ricolleau, G., Eche, N., Larbre, H., Basuyau, J.P., Dalifard, I., Hacene, K. and Pichon, M.F. (2006) CA 125 Half-Life and CA 125 Nadir during Induction Chemotherapy Are Independent Predictors of Epithelial Ovarian Cancer Outcome: Results of a French Multicentric Study. Annals of Oncology, 17, 1234-1238. https://doi.org/10.1093/annonc/mdl120
|
[44]
|
Fleming, N.D., Cass, I., Walsh, C.S., Karlan, B.Y. and Li, A.J. (2011) CA125 Surveillance Increases Optimal Resectability at Secondary Cytoreductive Surgery for Recurrent Epithelial Ovarian Cancer. Gynecologic Oncology, 121, 249-252. https://doi.org/10.1016/j.ygyno.2011.01.014
|